Compare Matson Inc (MATX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Medpace Holdings Inc — how do they compare? Matson Inc trades at $218.3 (market cap $6.61B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Medpace Holdings Inc is far larger — about 2.3× Matson Inc's market cap, and Matson Inc pays a 0.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MATX | MEDP | |
|---|---|---|
Market Cap | $6.61B | $15.08B |
Sector | Technology | Technology |
52-Week High | $223.55 | $620.59 |
52-Week Low | $88.05 | $308.88 |
Enterprise Value | $7.21B | $14.55B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $218.41, down 1.7% today but maintains strong technical momentum with bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.85 exceeding expectations. Recent dividend increases and share repurchases highlight management's confidence, while preliminary Q2 2026 results project continued strength in Pacific shipping operations.
The outlook remains positive with analyst consensus favoring buys (64%) and technical indicators supporting upward momentum. Key risks include exposure to Pacific trade volatility and shipping rate fluctuations, but Matson's niche positioning and operational efficiency provide competitive advantages for sustained growth.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
